Status:
RECRUITING
Duration of Adjuvant Chemotherapy for Gastric Cancer Patients at Pathological N3 Stage
Lead Sponsor:
The First Affiliated Hospital of Zhengzhou University
Conditions:
Gastric Cancer
Eligibility:
All Genders
18-80 years
Brief Summary
The goal of this retrospective study is to compare the efficacy and safety of 3-4 months to 5-6 months of CapOx/SOX adjuvant chemotherapy in pathological N3 gastric cancer patients.
Detailed Description
Due to a heavy metastatic node burden, pathological stage N3 (pN3) gastric cancer (GC) patients have extremely poor prognoses. Except for surgical resection, postoperative adjuvant chemotherapy is the...
Eligibility Criteria
Inclusion
- 18-80 years old
- Pathological stage N3 GC (≥7 positive lymph nodes) after curative surgery according to the AJCC TNM staging system, 8th edition
- Histologically confirmed R0 resection, defined as no macroscopic or microscopic residual tumor
- Postoperative chemotherapy with CapOX or SOX doublet regimen, initiating within 6 weeks after curative gastrectomy
- No distant metastases or gastric stump cancer
- No other malignant tumors
Exclusion
- Patients who had undergone neoadjuvant chemotherapy or radiotherapy
- Patients who received capecitabine or S-1 alone or combined with biological therapy, radiation therapy, or Immunosuppressive therapy
Key Trial Info
Start Date :
January 11 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 31 2024
Estimated Enrollment :
260 Patients enrolled
Trial Details
Trial ID
NCT06194981
Start Date
January 11 2024
End Date
May 31 2024
Last Update
January 12 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Gastrointestinal Surgery, the First Affiliated Hospital of Zhengzhou University
Zhengzhou, Henan, China, 450001